Recursion Pharmaceuticals Inc. $(RXRX)$ has announced the acquisition of Rallybio's full interest in their joint ENPP1 inhibitor program, REV102, designed for the treatment of hypophosphatasia $(HPP)$, a rare genetic disorder. The acquisition includes an associated backup molecule. This move grants Recursion full ownership of the program, allowing the company to expedite the development of what could become the first oral disease-modifying therapy for HPP. Currently in IND-enabling studies, REV102 is expected to enter Phase 1 clinical trials in the second half of 2026. The program aims to address the underlying cause of HPP by inhibiting the enzyme ENPP1, potentially improving bone mineralization. Results of these studies have yet to be presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.